Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Subgroup analysis of US and non-US patients in a global study of high-dose donepezil (23 mg) in moderate and severe Alzheimer's disease.

Salloway S, Mintzer J, Cummings JL, Geldmacher D, Sun Y, Yardley J, Mackell J.

Am J Alzheimers Dis Other Demen. 2012 Sep;27(6):421-32. doi: 10.1177/1533317512454708.

PMID:
22930699
2.

Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer's disease: a subgroup analysis in patients already taking or not taking concomitant memantine.

Doody RS, Geldmacher DS, Farlow MR, Sun Y, Moline M, Mackell J.

Dement Geriatr Cogn Disord. 2012;33(2-3):164-73. doi: 10.1159/000338236. Epub 2012 May 10.

PMID:
22572767
3.

Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer's disease.

Doody RS, Corey-Bloom J, Zhang R, Li H, Ieni J, Schindler R.

Drugs Aging. 2008;25(2):163-74.

PMID:
18257603
4.

Higher-dose (23 mg/day) donepezil formulation for the treatment of patients with moderate-to-severe Alzheimer's disease.

Christensen DD.

Postgrad Med. 2012 Nov;124(6):110-6. doi: 10.3810/pgm.2012.11.2589. Review.

PMID:
23322144
5.

Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil.

Weycker D, Taneja C, Edelsberg J, Erder MH, Schmitt FA, Setyawan J, Oster G.

Curr Med Res Opin. 2007 May;23(5):1187-97.

PMID:
17519086
6.

Efficacy and safety of donepezil in patients with Alzheimer's disease: results of a global, multinational, clinical experience study.

Boada-Rovira M, Brodaty H, Cras P, Baloyannis S, Emre M, Zhang R, Bahra R; 322 Study Group.

Drugs Aging. 2004;21(1):43-53.

PMID:
14715043
7.

Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.

Feldman H, Gauthier S, Hecker J, Vellas B, Xu Y, Ieni JR, Schwam EM; Donepezil MSAD Study Investigators Group.

Int J Geriatr Psychiatry. 2005 Jun;20(6):559-69.

PMID:
15920715
8.

[Effect of memantine treatment on patients with moderate-to-severe Alzheimer's disease treated with donepezil].

Creţu O, Szalontay AS, Chiriţă R, Chiriţă V.

Rev Med Chir Soc Med Nat Iasi. 2008 Jul-Sep;112(3):641-5. Romanian.

PMID:
20201245
9.

Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment.

Feldman HH, Schmitt FA, Olin JT; Memantine MEM-MD-02 Study Group.

Alzheimer Dis Assoc Disord. 2006 Oct-Dec;20(4):263-8.

PMID:
17132971
10.

Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease.

Bullock R, Bergman H, Touchon J, Gambina G, He Y, Nagel J, Lane R.

Curr Med Res Opin. 2006 Mar;22(3):483-94.

PMID:
16574032
11.

Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease.

Gauthier S, Feldman H, Hecker J, Vellas B, Emir B, Subbiah P; Donepezil MSAD Study Investigators' Group.

Curr Med Res Opin. 2002;18(6):347-54.

PMID:
12442882
12.

Donepezil treatment of patients with severe Alzheimer's disease in a Japanese population: results from a 24-week, double-blind, placebo-controlled, randomized trial.

Homma A, Imai Y, Tago H, Asada T, Shigeta M, Iwamoto T, Takita M, Arimoto I, Koma H, Ohbayashi T.

Dement Geriatr Cogn Disord. 2008;25(5):399-407. doi: 10.1159/000122961. Epub 2008 Apr 3.

PMID:
18391486
13.

Long-term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer's disease.

Tariot P, Salloway S, Yardley J, Mackell J, Moline M.

BMC Res Notes. 2012 Jun 8;5:283. doi: 10.1186/1756-0500-5-283.

14.

Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease.

Doody RS, Geldmacher DS, Gordon B, Perdomo CA, Pratt RD; Donepezil Study Group.

Arch Neurol. 2001 Mar;58(3):427-33.

PMID:
11255446
15.
16.

Donepezil preserves cognition and global function in patients with severe Alzheimer disease.

Black SE, Doody R, Li H, McRae T, Jambor KM, Xu Y, Sun Y, Perdomo CA, Richardson S.

Neurology. 2007 Jul 31;69(5):459-69.

PMID:
17664405
17.

Donepezil in Alzheimer's disease: eighteen month results from Southampton Memory Clinic.

Matthews HP, Korbey J, Wilkinson DG, Rowden J.

Int J Geriatr Psychiatry. 2000 Aug;15(8):713-20.

PMID:
10960883
18.

Tolerability of switching from donepezil to memantine treatment in patients with moderate to severe Alzheimer's disease.

Waldemar G, Hyvärinen M, Josiassen MK, Kørner A, Lehto H, Wetterberg P.

Int J Geriatr Psychiatry. 2008 Sep;23(9):979-81. doi: 10.1002/gps.1979. No abstract available.

PMID:
18229874
19.

A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.

Tariot PN, Cummings JL, Katz IR, Mintzer J, Perdomo CA, Schwam EM, Whalen E.

J Am Geriatr Soc. 2001 Dec;49(12):1590-9.

PMID:
11843990
20.

Effect of donepezil in patients with Alzheimer's disease previously untreated or treated with memantine or nootropic agents in Germany: an observational study.

Klinger T, Ibach B, Schoenknecht P, Kamleiter M, Silver G, Schroeder J, Mielke R.

Curr Med Res Opin. 2005 May;21(5):723-32.

PMID:
15969871

Supplemental Content

Support Center